GSK has launched $50m venture capital fund to invest in pioneering bioelectronic medicines and technologies.
Action Potential Venture Capital (APVC) Limited, which complements the work of GSK’s Bioelectronics R&D unit, will focus on investing in three areas:
– new start-up companies that aim to pursue the vision of bioelectronic medicines;
– existing companies with technologies that are interacting with the peripheral nervous system through first-generation devices that can stimulate or block electrical impulses; and
– companies advancing technology platforms that will underpin these treatment modalities.
The vehicle, based in Cambridge, Massachusetts and managed by a dedicated team, has just made its first investment in SetPoint Medical, a developer of implantable device for treating inflammatory diseases (read here).